www.wjpps.com Vol 3, Issue 5, 2014.
1092
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
THERAPEUTIC EFFECTS OF ZANTHOXYLUM TETRASPERMUM
W.A. STEM BARK ON CARBOHYDRATE METABOLIZING
ENZYMES IN MAMMARY CARCINOMA MICE
Mr.Narayanasamy K.1* and Dr.Ragavan B2
1*Dept of Biochemistry, Sree Narayana Guru College, Coimbatore, Tamil Nadu, India.
2 Dept of Biochemistry, P.S.G.College of Arts & Science, Coimbatore, Tamil Nadu, India.
ABSTRACT
Mammary carcinoma is a heterogeneous disease that appears to
progress from an in situ tumor to invasive cancer. Little is known
about the molecular events driving this progression. The genus
Zanthoxylum is known as “Timoor” that is used as mouth fresh, tooth
care and spice. Zanthoxylum tetraspermum (Wight & Arn.) belongs to
the family“Rutaceae” possesses some biological activities. The present
study evaluated the effect of Z.tetraspermum stem bark extract (300
and 600mg / kg body weight) in liver and kidney of N-methyl-N-
nitrosourea (MNU) induced mammary carcinoma mice on
carbohydrate metabolizing enzymes and pentose phosphate pathway
enzyme. Mammary carcinoma-bearing mice showed a significant (P<0.05) rise in glycolytic
enzymes like hexokinase, Phosphoglucoisomerase, aldolase and pentose phosphate pathway
enzyme glucose-6-phosphate dehydrogenase. Mammary carcinoma-bearing mice also causes
a simultaneous fall in gluconeogenic enzymes like glucose-6-phosphatase and fructose 1, 6-
diphosphatase.The activities of mitochondrial enzymes like succinate dehydrogenase and
malate dehydrogenase were significantly (P<0.05) lowered in mammary carcinoma-bearing
mice. Z.tetraspermum stem bark extract administration to tumor-induced mice significantly
(P<0.05) reversed the activities of glycolytic enzymes, pentose phosphate pathway enzyme,
gluconeogenic enzymes and the mitochondrial enzymes which indicated the antitumor
activity of the plant extract. The effect of oral Z.tetraspermum at the dose of 600mg / kg body
weight was more than the 300 mg / kg body weight. Comparison of normal mice, mice
administered only with plant stem bark extract and mice administered with 5-Fluoro Uracil
WWOORRLLDD JJOOUURRNNAALL OOFF PPHHAARRMMAACCYY AANNDD PPHHAARRMMAACCEEUUTTIICCAALL SSCCIIEENNCCEESS SSJJIIFF IImmppaacctt FFaaccttoorr 22..778866
VVoolluummee 33,, IIssssuuee 66,, 11009922--11111133.. RReesseeaarrcchh AArrttiiccllee IISSSSNN 2278 – 4357
Article Received on 25 March 2014, Revised on 20 April 2014, Accepted on 13 May 2014
*Correspondence for Author
Mr.Narayanasamy K.
Dept of Biochemistry, Sree
Narayana Guru College,
Coimbatore, Tamil Nadu,
India.
www.wjpps.com Vol 3, Issue 5, 2014.
1093
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
(5-FU) as positive drug control group showed no significant variations in enzyme activities.
The results obtained in the present study indicate the therapeutic effect of the stem bark
extract and validates the traditional use of this plant in mammary carcinoma animals.
Key words: Z. tetraspermum, MNU, Mammary carcinoma, metabolic enzymes.
INTRODUCTION
Breast cancer is the most prevalent cancer in women worldwide, excluding nonmelanoma
skin cancer, and is the second leading cause of cancer deaths in women1. Once metastasis has
occurred, the survival rate is drastically reduced to a median of 2–3 years; therapy is then
aimed at controlling symptoms, prolonging survival and improving quality of life2.This is a
complex disease thought to occur via a multistep process and the use of adjuvant therapy,
continues to be fatal in many patients. Metastatic disease is the most common cause of breast
cancer death3 and is preceded by a sequence of events leading to the transformation of normal
breast epithelium. Histologically, progression may proceed through stages of atypical ductal
hyperplasia; ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) 4. The first
critical step in this process is invasion, which requires the loss of cellular adhesion and gain
of motility.
Traditional medicines have been the starting point for the discovery of many important
modern drugs. This has led to chemical and pharmacological investigations and general
biological screening of medicinal plants all over the world. Approximately 80% of the
world’s population relies on the use of traditional medicine, which is predominantly based on
plant materials. In recent years there has been considerable emphasis on the identification of
plant products as possible anticarcinogens with antioxidant properties5.
Zanthoxylum has been studied for several types of biological activities such as larvicidal,
anti-inflammatory, analgesic, antinociceptive, antioxidant, antibiotic, hepatoprotective,
antiplasmodial, cytotoxic, antiproliferative, anthelminthic, antiviral, anticonvulsant and
antifungal6-17. Zanthoxylum tetraspermum is a potent unidentified medicinal plant. It is
vernacularly called “Tooth ache tree” and belonging to the family of “Rutaceae”. It is an
aromatic, spiny, thorny, stout, deciduous climbing shrub or small tree, with brown bark and
alternate branches are armed with strong brown prickles. The wood is yellowish and soft18.
The plant is found in the Western Ghats in the Nilgiris, Aanaimalai hills, Kolli hills at
attitudes of 1,200 to 1,800m and in Kerala and Karnataka. The plant is credited in Srilanka
www.wjpps.com Vol 3, Issue 5, 2014.
1094
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
with stimulant, astringent and digestive properties and is prescribed in dyspepsia and
diarrheas19-21
Z.tetraspermum is used for treating microbial infections, antifungal activities, tumors and
tooth ache.The phytochemical investigations of Z.tetraspermum stem bark have revealed the
presence of two benzophenanthrene alkaloids such as 8-acetonyl dihydronitidine, 8-acetonyl
dihydro avicine22 and decrine from Z. tetraspermum, Z. caudatum and Zanthoxylum
limonella23.The presence of the alkaloids such as Liriodenine, sesamin, lichexanthone and
piperitol gamma-gamma-diethyl ether from the Z. tetraspermum has been reported and they
have shown significant anti-bacterial and anti-fungal activity24. The presence of an alkaloid
Norsanguinarine, a polyhydroxy and a phenolic compound cyclohexanetetrol,
methoxyphenol, Gallopamil in the aqueous extract and a phenolic compound 2-methoxy-4-
vinylphenol in the ethanolic extract, from the Z. tetraspermum has also been reported25.
Toothpaste containing Z. nitidum extract decreased the incidence of dental plaque and
enhanced gingival health26. An alkaloidal extract of the stem barks of Z.chiloperone
exhibited antifungal activity against Candida albicans, Aspergillus fumigatus and
Trichophyton mentagrophytes27. Bafi-Yeboa et.al.28 investigated Z. americanum leaf, fruit,
stem, bark and root for antifungal activity with 11 strains of fungi. All extracts exhibited a
broad spectrum of antifungal activity. Alkamides isolated from the leaves of Z. syncarpum
showed moderate antiplasmodial activity, with IC50 values of 4.2 and 6.1 mM against
plasmodium falciparum D6 and W2 clone29. Ethanolic extracts of the trunk bark of Z. fagara,
Z.elephantiasis and Z. martinicense showed antifungal activity30. The petroleum ether,
chloroform and methanol extracts of the leaves and barks of Z. budrunga have been evaluated
for their antibacterial, antifungal and cytotoxic properties31. Benzophenanthrene alkaloids, 8-
acetonyldihydronitidine and 8-acetonyldihydroavicine were isolated from Z. tetraspermum
stem bark which showed significant antibacterial activity32.
Cytotoxic activity of essential oil of Z. rhoifolium was evaluated against HeLa (human
cervical carcinoma), A-549 (human lung carcinoma), HT-29 (human colon adenocarcinoma),
and Vero (monkey kidney) cell lines and mice macrophages by Da Silva et.al. 33. They
observed that the essential oil is cytotoxic against tumor cells (CD50 = 82.3, 90.7 and 113.6
µg/ml for A-549, HeLa, HT-29 cell lines, respectively). The fruit essential oils of Z. leprieurii
and Z. xanthoxyloides could be used as food supplements to protect against emergent diseases
such as cardiovascular problems, cancer and diabetes34.
www.wjpps.com Vol 3, Issue 5, 2014.
1095
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
Carbohydrate metabolism plays a characteristic role in cancerous conditions35. One of the
most common and profound phenotypes of highly growing malignant tissues is that their
capacity to utilize and catabolize glucose at high rates. The high glycolytic rate is important
for rapidly proliferating cancers not only as major energy source but also to provide such
cells with precursors for nucleotide and lipid biosynthesis. Mitochondria are the intracellular
organelles responsible for ATP synthesis through the coupling of oxidative phosphorylation
to respiration in human and animal cells. The principal mitochondrial substrate is pyruvate
formed by glycolysis that enters the tricarboxylic acid cycle (TCA cycle) and the respiratory
chain to promote the generation of ATP. Mitochondria are the major intracellular source
during oxidative phosphorylation and are the primary target of reactive oxygen species
(ROS), which are generated under normal conditions as by-products of aerobic metabolism in
animal and human cells36. The defects in the respiratory chain lead to enhanced production of
ROS and free radicals in mitochondria, resulting in mitochondrial DNA mutations which
indirectly impair glucose sensing by reducing intracellular concentrations of ATP, an
important metabolic fuel37.
Since the therapeutic efficacy of Zanthoxylum tetraspermum was not yet carried out, the
objective of this study is focused on the metabolic enzymes associated with the carbohydrate
metabolizing and mitochondrial TCA cycle enzymes and cytotoxic activity of the plant
extract.
MATERIALS AND METHODS
Plant Material and Extraction
The whole plant material of Zanthoxylum tetraspermum. Wight & Arn. [Syn.Fagara
tetrasperma] 38 was collected from the silent valley ever green forest of Western Ghats,
Palakkad district, Kerala, South India. The plant was identified with the help of Institute of
Forest Genetics and Tree Breeding, Coimbatore, Tamil Nadu, South India. The stem bark of
the plant was shade dried at room temperature for 15 days. Then, they were powdered using
mixer grinder and subjected to extraction. The coarse powder (500gm) was extracted with
mixture of ethanol and water (1:1 ratio) for 72 hrs.The extract was then concentrated in vacuo
until the solvent was completely removed. The yield of the extract was found to be 12.6
grams.
www.wjpps.com Vol 3, Issue 5, 2014.
1096
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
Animals
Female albino Sprague-Dawley mice between 40-50 days old were used for the experiments.
The animals were housed in individual, well ventilated cages (12-h light: dark cycle) and
were fed a commercial pelleted diet (M/s. Hindustan Lever foods, Mumbai, India) with water
freely available. This project received approval from the Animal Ethics Committee by
CPCSEA96/IAEC No.158/99/10.
Induction of mammary carcinoma
Mammary carcinoma was induced in female mice by a single intraperitoneal dose of N-
methyl-N-nitrosourea (MNU) injected into each of 30 female albino Sprague–Dawley mice
(aged 50 days). At day 50, all mice received a single dose of MNU 50 mg/kg
intraperitoneally. (MNU, reagent grade, was obtained from Sigma, USA, dissolved in 0.9%
saline). Two weeks after MNU treatment, a time by which the animals had recovered from
MNU-induced toxicity, the mice were divided into groups. The tumor was allowed to grow
for three months and the mice were palpated regularly to determine the appearance of
mammary tumor. After three months, mammary carcinoma was confirmed by histological
examination.
Experimental design
The animals were divided into eight groups of six animals each. The groups were formed as
follows:
Group – I = Normal healthy Mice.
Group – II =Control Mice (MNU Induced, 50mg MNU/ kg; ip)
Group –III =Extract treated Mice (MNU + 300mg extract/kg; oral; daily) for 4 weeks.
Group –IV =Extract treated Mice (MNU + 600mg extract/kg; oral; daily) for 4 weeks.
Group –V =Drug treated Mice (MNU + 5-Fluoro Uracil 300mg/kg; oral; daily) for 4 weeks.
Group –VI =Drug treated Mice (MNU + 5-Fluoro Uracil 600mg/kg; oral; daily) for 4 weeks.
Group –VII =Plant extract only (Plant extract 300mg/kg; oral; daily) for 4 weeks.
Group –VIII =Plant extract only (Plant extract 600mg/kg; oral; daily) for 4 weeks.
Groups III to VI were induced with mammary carcinoma and after three months, treatment
began with plant extract, 5-FU administered orally for four weeks as indicated above. Groups
VII and VIII animals were administered with Z.tetraspermum only on the same dosage as
Groups III and IV animals and by a similar route.
www.wjpps.com Vol 3, Issue 5, 2014.
1097
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
Biochemical analysis
At the end of the experimental period, animals were fasted overnight and then killed by
cervical decapitation. The liver and kidneys from all the animals were removed, washed in
ice-cold isotonic saline and blotted individually on ash-free filter paper. The tissues were
homogenized in 0.1M Tris HCl buffer (pH 7.4) and used for estimation of carbohydrate
metabolizing and mitochondrial enzymes.
Carbohydrate metabolizing enzyme assays
Hexokinase activity was measured with respect to the amount of glucose utilized after the
addition of ATP39. Aldolase activity was assayed according to the method of King (1965) 40
with fructose-1, 6-diphosphatase as substrate and dinitrophenyl hydrazine as coloring reagent.
Phosphoglucoisomerase was measured using 2, 6-dichlorophenol indophenols dye according
to the method of Gracy and Tilley (1975) 41. The activity of glucose-6-phosphate
dehydrogenase was assayed by the method of Ells and Kirkman (1961) 42 with respect to the
amount of inorganic phosphorus liberated after the addition of the substrate glucose-6-
phosphate. The activities of glucose-6-phosphatase and fructose-1, 6-diphosphatase were
assayed43 with respect to the amount of inorganic phosphorus liberated after the addition of
their respective substrates glucose-6-phosphate or fructose-1, 6-diphosphate.
Mitochondrial TCA cycle enzyme assays
The purity of mitochondria was assessed by estimating succinate dehydrogenase activity by
the method of Slater and Bonner (1952) 44 in which the rate of reduction of potassium
ferricyanide is assessed. The activity of malate dehydrogenase was estimated by the method
of Mehler et.al., (1948)45.
STATISTICAL ANALYSIS
The statistical evaluation was done using one-way analysis of variance (ANOVA). Individual
differences between treatments were examined using Tukey’s HSD test. In all cases P< 0.05
denoted significance.
RESULTS
Glycolytic enzymes
The activities of glycolytic enzymes such as hexokinase, aldolase and
phosphoglucoisomerase were significantly (P<0.05) increased in the liver and kidney of
cancerous group II animals. Administration of two different doses (300mg and 600mg / kg
www.wjpps.com Vol 3, Issue 5, 2014.
1098
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
body weight) of plant extract for 4 weeks in mammary carcinoma-bearing mice (group III
and IV) showed significantly (P<0.05) reduced activity of hexokinase, aldolase and
phosphoglucoisomerase when compared with cancerous group II. Similarly, administration of
same doses of 5-FU for 4 weeks in mammary carcinoma-bearing mice (group V and VI) also
showed the significantly (P<0.05) reduced activity of glycolytic enzymes. Group IV mice had
showed significantly (P<0.05) effective activity than the group III animals. However, the
plant extract alone treated animals (groups VII and VIII) did not show any significant
changes when compared with normal mice (group I). No significant variation is shown when
the group III and IV mice compared with Group V and VI respectively (Tables-1&2,
Figures.1-3, 5-7).
Pentose phosphate pathway enzyme
The activity of pentose phosphate pathway enzyme glucose-6-phosphate dehydrogenase was
significantly (P<0.05) increased in the liver and kidney of group II mice. Administration of
the doses 300mg and 600mg / kg body weight of plant extract in mammary carcinoma-
bearing mice (group III and IV) showed significantly (P<0.05) reduced activity of glucose-6-
phosphate dehydrogenase when compared with cancerous group II mice. The administration
of same doses of 5-FU for 4 weeks in mammary carcinoma-bearing mice (group V and VI)
also showed the significantly (P<0.05) reduced activity of glucose-6-phosphate
dehydrogenase enzyme. Group IV mice had showed significantly (P<0.05) effective activity
than the group III animals. And the plant extract alone treated animals (groups VII and VIII)
did not show any significant variation when compared with normal (group I) mice. No
significant variation is shown when the group III and IV animals compared with Group V and
VI respectively (Tables-1&2, Figures.4 & 8).
Gluconeogenic enzymes
The activities of gluconeogenic enzymes like glucose-6-phosphatase and fructose-1, 6-
diphosphatase in the liver and kidney of cancerous group II animals were significantly
(P<0.05) decreased when compared with normal mice (group I). Administration of two
different doses of plant extract (300mg and 600mg / kg body weight) in group III and IV
mice showed significantly (P<0.05) increased activity of gluconeogenic enzymes when
compared with cancerous group II. Administration of 5-FU (300mg and 600mg / kg body
weight) for 4 weeks in mammary carcinoma-bearing group V and VI mice also showed the
significantly (P<0.05) increased activity of gluconeogenic enzymes. The oral dose of the
www.wjpps.com Vol 3, Issue 5, 2014.
1099
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
extract with 600mg / kg body weight (group IV mice) was more than the 300 mg / kg body
weight (group III mice). The plant extract alone treated animals (groups VII and VIII) did not
show any significance when compared with normal mice (group I). No significant variation is
shown when the group III and IV mice compared with Group V and VI respectively (Tables-
3& 4, Figures.9-12).
Mitochondrial TCA cycle enzymes
The activities of TCA cycle enzymes like succinate dehydrogenase and malate
dehydrogenase in the liver and kidney mitochondria of normal and experimental animals are
shown in Tables-5 & 6 respectively (Figures.13-16). The activity of mitochondrial enzymes
succinate dehydrogenase and malate dehydrogenase were significantly decreased in the liver
and kidney of cancerous group II mice (P<0.05) when compared with the normal (group I)
animals. Mammary carcinoma-bearing mice (group III and IV) treated with two different
doses (300mg, 600mg) of plant extract showed a significant increase in mitochondrial
enzymes activity when compared with group II animals (P<0.05). Mammary carcinoma-
bearing mice (group V and VI) treated with two different doses (300mg, 600mg) of 5-FU also
showed a significant increase in mitochondrial enzymes activity when compared with group
II mice (P<0.05). No significant variation is shown when the group III and IV compared with
Group V and VI respectively. Group IV mice treated with a dose of 600mg has significantly
showed an effective activity when compared with the group III animals treated with a dose
of 300mg (P<0.05). Groups VII and VIII treated with the plant extract alone (2 different
doses) showed no significant variation when compared with normal mice (group I).
Table-1: Liver Hexokinase, Aldolase, Phosphoglucoisomerase and Glucose-6-phosphate
dehydrogenase activity in control and experimental mice
Treatment / Groups
Hexokinase (µg of glucose -6-
phosphate /min / mg protein)
Aldolase (µmoles of
glyceraldehyde formed /min / mg protein at 37°C)
Phospho glucoisomerase
(Fructose / min / mg protein)
Glucose-6-phosphate
dehydrogenase (units / minute / mg
protein) I- Normal 4.3417 0.56380 0.2134 0.04393 0.2500 0.03742 0.3305 0.05546 II- Tumor induced 8.8950 0.70222 a * 0.5933 0.04844 a * 0.3833 0.03327 a * 1.0983 0.05419 a
* III- MNU + 300mg extract 5.0083 0.55003 b,f * 0.3700 0.04336 b,f * 0.2400 0.02366 b,f * 0.4917 0.06047 b,f
* IV- MNU + 600mg extract 4.2883 0.40216 b,f * 0.3350 0.04231 b,f * 0.2050 0.05431 b,f * 0.3550 0.02074 b,f
*
www.wjpps.com Vol 3, Issue 5, 2014.
1100
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
Values are expressed as Mean S.D (n = 6); Statistical comparison by Tukey’s HSD: a –
Group II is compared with Group I; b – Group III, IV is compared with Group II; c – Group
III is compared with Group V; d – Group IV is compared with Group VI; e – Group VII, VIII
is compared with Group I; f – Group III is compared with Group IV. NS – Non-
significant. *P < 0.05.
Table-2: Kidney Hexokinase, Aldolase, Phosphoglucoisomerase and Glucose-6-
phosphate dehydrogenase activity in control and experimental mice
Values are expressed as Mean S.D (n = 6); Statistical comparison by Tukey’s HSD: a –
Group II is compared with Group I; b – Group III, IV is compared with Group II; c – Group
III is compared with Group V; d – Group IV is compared with Group VI; e – Group VII, VIII
is compared with Group I; f – Group III is compared with Group IV. NS – Non-
significant. *P < 0.05.
V- MNU + 300 mg 5FU
4.0083 0.52396 c NS
0.3600 0.03162 c NS
0.2033 0.04633 c NS
0.3350 0.01225 c NS
VI- MNU + 600 mg 5FU
4.2367 0.07174 d NS
0.3250 0.00548 d NS
0.2167 0.00816 d NS
0.3183 0.03764 d NS
VII- 300 mg extract
3.9750 0.26075 e NS
0.2417 0.02483 e NS
0.1833 0.04926 e NS
0.2744 0.04410 e NS
VIII- 600 mg extract
4.3805 0.44793 e NS
0.2467 0.03266 e NS
0.1850 0.04324 e NS
0.3150 0.03209 e NS
Treatment / Groups
Hexokinase (µg of glucose -6-
phosphate /min / mg protein)
Aldolase (µmoles of
glyceraldehyde formed /min / mg protein at 37°C)
Phospho glucoisomerase
(Fructose / min / mg protein)
Glucose-6-phosphate
dehydrogenase (units / minute / mg
protein) I- Normal 2.1532 1.27034 0.1221 0.01025 0.1230 0.07438 0.0991 0.04543 II- Tumor induced 3.7872 0.31740 a * 0.3450 0.02739 a * 0.2467 0.02733 a * 0.2050 0.03564 a *
III- MNU + 300mg extract 2.8117 0.05981 b,f * 0.0758 0.03393 b,f * 0.1700 0.02683 b,f * 0.1407 0.02823 b,f *
IV- MNU + 600mg extract 2.1217 0.08565 b,f * 0.1281 0.00369 b,f * 0.1385 0.01813 b,f * 0.1315 0.02071 b,f *
V- MNU + 300 mg 5FU
2.3219 0.26548 c
NS 0.1056 0.02188 c
NS 0.1417 0.02704 c
NS 0.1450 0.02258 c
NS VI- MNU + 600 mg 5FU
2.0350 0.24566 d
NS 0.1288 0.00674 d
NS 0.1542 0.04124 d
NS 0.1417 0.01722 d
NS VII- 300 mg extract
2.4883 0.27795 e NS
0.1104 0.01760 e NS
0.1483 0.02483 e NS
0.1400 0.02366 e NS
VIII- 600 mg extract
2.2267 0.24736 e NS
0.0997 0.02406 e NS
0.1533 0.02875 e NS
0.1383 0.02714 e NS
www.wjpps.com Vol 3, Issue 5, 2014.
1101
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
Table- 3: Liver Glucose-6-phosphatase and Fructose-1, 6- diphosphatase activity in
control and experimental mice
Values are expressed as Mean S.D (n = 6); Statistical comparison by Tukey’s HSD: a – Group II is compared with Group I; b – Group III, IV is compared with Group II; c – Group III is compared with Group V; d – Group IV is compared with Group VI; e – Group VII, VIII is compared with Group I; f – Group III is compared with Group IV. NS – Non-significant. *P < 0.05. Table – 4: Kidney Glucose-6-phosphatase and Fructose-1, 6- diphosphatase activity in
control and experimental mice
Values are expressed as Mean S.D (n = 6); Statistical comparison by Tukey’s HSD: a – Group II is compared with Group I; b – Group III, IV is compared with Group II; c – Group III is compared with Group V; d – Group IV is compared with Group VI; e – Group VII,
Treatment / Groups Glucose-6-phosphatase
(Nano moles of Pi liberated /min / mg protein)
Fructose-1,6 – Diphosphatase (µmoles of Pi liberated /min /
mg protein) I- Normal 1.9283 1.32388 1.1017 0.07250
II- Tumor induced 0.2714 0.06628 a * 0.3067 0.04926 a *
III- MNU + 300mg extract 1.5167 0.38051 b,f * 0.7300 0.00894 b,f *
IV- MNU + 600mg extract 1.5883 0.09988 b,f * 0.9583 0.02229 b,f *
V- MNU + 300 mg 5FU 1.6767 0.12111 c NS 0.7950 0.03886 c NS
VI- MNU + 600 mg 5FU 1.7017 0.08864 d NS 0.9883 0.03312 d NS
VII- 300 mg extract 1.6567 0.06250 e NS 1.0783 0.03869 e NS
VIII- 600 mg extract 1.8270 1.13960 e NS 1.0800 0.06197 e NS
Treatment / Groups Glucose-6-phosphatase
(Nano moles of Pi liberated /min / mg protein)
Fructose-1,6 – Diphosphatase (µmoles of Pi liberated /min /
mg protein) I- Normal 2.7438 1.20828 1.4433 0.02422
II- Tumor induced 1.1700 0.04899 a * 0.4450 0.02429 a *
III- MNU + 300mg extract 2.3050 0.09772 b,f * 1.1550 0.02881 b,f *
IV- MNU + 600mg extract 2.5083 0.19590 b,f * 1.2483 0.01722 b,f *
V- MNU + 300 mg 5FU 2.6017 0.21018 c NS 1.1533 0.04844 c NS
VI- MNU + 600 mg 5FU 2.6633 0.03983 d NS 1.3233 0.01506 d NS
VII- 300 mg extract 2.2411 0.90671 e NS 1.4033 0.01966 e NS
VIII- 600 mg extract 2.4088 0.41996 e NS 1.4117 0.01472 e NS
www.wjpps.com Vol 3, Issue 5, 2014.
1102
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
VIII is compared with Group I; f – Group III is compared with Group IV. NS – Non-significant. *P < 0.05. Table- 5: Liver Succinate dehydrogenase and Malate dehydrogenase activity in control
and experimental mice
Values are expressed as Mean S.D (n = 6); Statistical comparison by Tukey’s HSD: a – Group II is compared with Group I; b – Group III, IV is compared with Group II; c – Group III is compared with Group V; d – Group IV is compared with Group VI; e – Group VII, VIII is compared with Group I; f – Group III is compared with Group IV. NS – Non-significant. *P < 0.05. Table- 6: Kidney Succinate dehydrogenase and Malate dehydrogenase activity in
control and experimental mice
Values are expressed as Mean S.D (n = 6); Statistical comparison by Tukey’s HSD: a – Group II is compared with Group I; b – Group III, IV is compared with Group II; c – Group III is compared with Group V; d – Group IV is compared with Group VI; e – Group VII, VIII is compared with Group I; f – Group III is compared with Group IV. NS – Non-significant. *P < 0.05.
Treatment / Groups Succinate dehydrogenase
(SDH) (µmoles / min / mg protein)
Malate dehydrogenase (MDH)
(µmoles of NADH oxidized / min / mg protein)
I- Normal 0.41517 0.027795 0.39167 0.005354 II- Tumor induced 0.20017 0.003189 a * 0.15533 0.003077 a * III- MNU + 300mg extract 0.29533 0.004179 b,f * 0.22533 0.003933 b,f * IV- MNU + 600mg extract 0.35467 0.004274 b,f * 0.26917 0.002927 b,f * V- MNU + 300 mg 5FU 0.31133 0.012533 c NS 0.22800 0.002366 c NS VI- MNU + 600 mg 5FU 0.35933 0.008042 d NS 0.27167 0.002160 d NS VII- 300 mg extract 0.39983 0.002137 e NS 0.38317 0.003488 e NS VIII- 600 mg extract 0.41133 0.006408 e NS 0.38383 0.008472 e NS
Treatment / Groups
Succinate dehydrogenase (SDH)
(µmoles / min / mg protein)
Malate dehydrogenase (MDH)
(µmoles of NADH oxidized / min / mg protein)
I- Normal 0.31017 0.010108 0.23767 0.030303 II- Tumor induced 0.15550 0.004231 a * 0.10083 0.005115 a * III- MNU + 300mg extract 0.22433 0.002582 b,f * 0.14083 0.006274 b,f * IV- MNU + 600mg extract 0.25333 0.002805 b,f * 0.14967 0.003502 b,f * V- MNU + 300 mg 5FU 0.23083 0.003764 c NS 0.15750 0.001517 c NS VI- MNU + 600 mg 5FU 0.26667 0.003615 d NS 0.17083 0.004262 d NS
VII- 300 mg extract 0.30150 0.004637 e NS 0.21583 0.015355 e NS VIII- 600 mg extract 0.30517 0.004446 e NS 0.22817 0.005845 e NS
www.wjpps.com Vol 3, Issue 5, 2014.
1103
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
I I I I I I I V V VI VI I VI I I0
2
4
6
8
10
Liver hexokinase activity
Normal Tumor Induced Extract(300mg)Extract(600mg) 5FU(300mg) 5FU(600mg)Plant only(300mg) Plant only(600mg)
I II III IV V VI VII VIII0
0.1
0.2
0.3
0.4
0.5
0.6
Act
ivity
/min
/mg
prot
ein
Liver aldolase activity
Normal Tumor Induced Extract(300mg) Extract(600mg)
5FU(300mg) 5FU(600mg) Plant only(300mg) Plant only(600mg)
Fig .1: Liver Hexokinase activity in control Fig.2: Liver Aldolase activity in control and and experimental mice. experimental mice.
I II III IV V VI VII VIII
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
Act
ivity
/min
/mg
prot
ein
Liver phosphoglucoisomerase activity
Normal Tumor Induced Extract(300mg) Extract(600mg)
5FU(300mg) 5FU(600mg) Plant only(300mg) Plant only(600mg)
III III IV V VI VII VIII
0
0.2
0.4
0.6
0.8
1
1.2Ac
tivit
y /m
in/m
g pr
otei
n
Liver glucose.6.phosphate dehydrogenase activity
Normal Tumor Induced Extract(300mg)Extract(600mg) 5FU(300mg) 5FU(600mg)Plant only(300mg) Plant only(600mg)
Fig.3: Liver Phosphoglucoisomerase activity Fig.4: Liver Glc.6.P.DHase activity in control and experimental mice. in control and experimental mice.
II I I I I I V V VI VI I VI I I
00.5
11.5
22.5
3
3.54
Act
ivit
y /m
in/m
g pr
otei
n
Kidney hexokinase activity
Normal Tumor Induced Extract(300mg)Extract(600mg) 5FU(300mg) 5FU(600mg)Plant only(300mg) Plant only(600mg)
I I II I I I V V VI VI I VI I I
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
Kidney aldolase act ivity
Normal Tumor Induced Extract(300mg)Extract(600mg) 5FU(300mg) 5FU(600mg)Plant only(300mg) Plant only(600mg)
Fig.5: Kidney Hexokinase activity in control Fig.6: Kidney Aldolase activity in control and
and experimental mice. experimental mice.
www.wjpps.com Vol 3, Issue 5, 2014.
1104
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
II I
I I I I V V VI VI I VI I I
0
0.05
0.1
0.15
0.2
0.25
Kidney phosphoglucoisomerase act ivity
Normal Tumor Induced Extract(300mg)Extract(600mg) 5FU(300mg) 5FU(600mg)Plant only(300mg) Plant only(600mg)
II I I I I I V V VI VI I VI I I
0
0.05
0.1
0.15
0.2
0.25
Kidney glucose.6.phosphate dehydrogenase act ivity
Normal Tumor Induced Extract(300mg)Extract(600mg) 5FU(300mg) 5FU(600mg)Plant only(300mg) Plant only(600mg)
Fig.7: Kidney Phosphoglucoisomerase activity Fig.8: Kidney Glc.6.P.DHase in control and experimental mice. activity in control and experimental mice
I II III IV V VI VII VIII0
0.5
1
1.5
2
Act
ivity
/min
/mg
prot
ein
Liver glucose.6.phosphatase activity
Normal Tumor Induced Extract(300mg) Extract(600mg)
5FU(300mg) 5FU(600mg) Plant only(300mg) Plant only(600mg)
I II III IV V VI VII VIII0
0.2
0.4
0.6
0.8
1
1.2A
ctiv
ity /m
in/m
g pr
otei
n
Liver fructose.1,6.diphosphatase activity
Normal Tumor Induced Extract(300mg) Extract(600mg)
5FU(300mg) 5FU(600mg) Plant only(300mg) Plant only(600mg)
Fig.9: Liver Glc.6.phosphatase activity in control Fig.10: Liver Fruc.1, 6. diphosphatase
and experimental mice. activity in control and experimental mice.
I II III IV V VI VII VIII
0
0.5
1
1.5
2
2.5
3
Kidney glucose.6.phosphatase activity
Normal Tumor Induced Extract(300mg)Extract(600mg) 5FU(300mg) 5FU(600mg)Plant only(300mg) Plant only(600mg)
I I I I I I I V V VI VI I VI I I
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
Act
ivit
y /m
in/m
g pr
otei
n
Kidney fructose.1,6.diphosphatase act ivity
Normal Tumor Induced Extract(300mg)Extract(600mg) 5FU(300mg) 5FU(600mg)Plant only(300mg) Plant only(600mg)
Fig.11: Kidney Glc.6.phosphatase activity Fig.12: Kidney Fruc.1,6.diphosphatase
in control and experimental mice. activity in control and experimental mice
www.wjpps.com Vol 3, Issue 5, 2014.
1105
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
III
III IV V VI VII VIII00.05
0.10.15
0.20.25
0.30.35
0.40.45
Act
ivity
/min
/mg
prot
ein
Liver succinate dehydrogenase activity
Normal Tumor Induced Extract(300mg) Extract(600mg)
5FU(300mg) 5FU(600mg) Plant only(300mg) Plant only(600mg)
I II III IV V VI VII VIII
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
Act
ivity
/min
/mg
prot
ein
Liver malate dehydrogenase activity
Normal Tumor Induced Extract(300mg)Extract(600mg) 5FU(300mg) 5FU(600mg)Plant only(300mg) Plant only(600mg)
Fig.13: Liver SDH activity in control Fig.14: Liver MDH activity in control and
and experimental mice experimental mice
I II III IV V VI VII VIII0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
Act
ivity
/min
/mg
prot
ein
Kidney succinate dehydrogenase activity
Normal Tumor Induced Extract(300mg) Extract(600mg)
5FU(300mg) 5FU(600mg) Plant only(300mg) Plant only(600mg)
I II III IV V VI VII VIII0
0.05
0.1
0.15
0.2
0.25A
ctiv
ity /m
in/m
g pr
otei
n
Kidney malate dehydrogenase activity
Normal Tumor Induced Extract(300mg) Extract(600mg)
5FU(300mg) 5FU(600mg) Plant only(300mg) Plant only(600mg)
Fig.15: Kidney SDH activity in control Fig.16: Kidney MDH activity in control and experimental mice and experimental mice. DISCUSSION
Malignant cells have a diminished respiratory rate, coupled with an excessive rate of aerobic
glycolysis. Mammary carcinoma-bearing mice have showed an increase in the activity of
glycolytic enzymes hexokinase, aldolase and phosphoglucoisomerase. This allowed us to
infer the elevated rate of glycolysis in tumor conditions since tumor cell proliferation is
dependent on glucose availability; these cells acquire the major part of their energy from the
glycolytic pathway46. The degree of elevation of these enzymes is directly related to the
extent of morphological differentiation and growth rate of hepatomas47. Hexokinase plays a
critical role in initiating and maintaining the high glucose catabolic rates of rapidly growing
tumors48 and accomplishes the entry of glucose into the glycolytic pathway by
phosphorylation to glucose-6-phosphate.The proliferating cells undergo a shift from oxidative
www.wjpps.com Vol 3, Issue 5, 2014.
1106
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
to glycolytic metabolism, where the energy requirements of the rapidly dividing cells are
provided by the ATP from glycolysis49.
The mitochondrial porin-bound hexokinase II is increased under the control of mutated
p53.This would direct mitochondrial ATP preferentially to form glucose-6-phosphate and
hence is expected to increase the biosynthetic pentose phosphate pathway. Hence, the
glycolytic capacity of cancer cells depends totally on hexokinase activity for its metabolic
fuel50. In this study, the observed increase in the activity of hexokinase in mammary
carcinoma animals might have been due to the increased metabolic need of energy fuel for
proliferating tumor cells and simultaneously increased activity of hexokinase51.
Administration of two different doses (300mg, 600mg) of plant extract and similar doses of
5-FU for 4 weeks to mammary carcinoma-bearing mice significantly (P<0.05) reduced the
enzyme activity and this may have been due to the antitumor activity of the alkaloids,
phenolic compounds and other phytochemicals present in the hydroethanolic stem bark
extract of Z.tetraspermum.Similar type of results on hexokinase were reported in mammary
carcinoma rats by Arathi and Sachdanandam (2003) 51.
Aldolase, another key enzyme in the glycolytic pathway, was increased in diethylnitrisamine-
induced tumor conditions. Aldolase was found to be elevated in tumor-bearing animals and in
breast cancer52. The elevated activity of phosphoglucoisomerase and aldolase may be due
to cell impairment and necrosis. In experimental carcinogenesis the cells are subjected to
carcinogen-induced damage, and very often exhibit glycolysis after a period of increased
oxygen uptake. The present result on Aldolase activity is in accordance with the study of
Semecarpus anacardium Linn. nut milk extract on carbohydrate metabolizing enzymes in
mammary carcinoma rats51.
Phosphoglucoisomerase serves as a good index of tumor growth and is significantly elevated
in cancerous cells. In agreement with this study, Campbell & King, (1962)53 reported that
phosphoglucoisomerase was an indicator of metastatic growth and was elevated in patients
with neoplasms, especially after metastasis. Alterations in the activity of
phosphoglucoisomerase might be expected to influence the proportion of glucose-6-
phosphate metabolized via the glycolytic pathway54. The high glycolytic rate of most tumors
can be adopted as a major source of energy in the deranged cell. Increase in the activity of
glycolysis results from rise of the tumor growth rate and is accompanied by a decrease in the
activity of the pentose phosphate pathway and respiratory chain55.
www.wjpps.com Vol 3, Issue 5, 2014.
1107
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
The plant extract treated animals showed a significant drop in the activity of glycolytic
enzymes and concomitant elevation in the activity of gluconeogenic enzymes. This
modulation may be due to the antitumor activity of the plant stem bark extract either by
inhibiting the glycolytic enzyme activity or by suppression of tumor progression56.The
activity may be attributed to the presence of alkaloids, polyphenolic content and other
aromatic phytochemical constituents in the plant stem bark extract, which has an effective
role over aerobic glycolysis in a dose dependant manner57.Comparison of group I, with
groups VII and VIII showed no significant variations in enzyme activity. The present
results are in agreement with the study reported by Sujatha and Sachdanandam (2002) 58.
The activity of gluconeogenic enzymes such as glucose-6-phosphatase and fructose-1, 6-
diphosphatase were inhibited significantly in tumor-bearing animals.Lactate production from
glucose rises and concomitantly glucose production from pyruvate decreases during the
progression of tumor growth. The observed reduction in the activity of these enzymes in
tumor-bearing animals may be due to the higher lactate production of neoplastic tissues, and
it has been proved that tumor utilizes a large proportion of lactate for glycolysis and protein
synthesis. A crucial point in regulation of aerobic glycolysis and of energy metabolism in
general is represented by the transport of metabolites across the mitochondrial membrane
from the cytosol to the matrix space of mitochondria. The present study is coinciding with the
findings on the therapeutic effect of Semecarpus anacardium Linn. nut milk extract on
carbohydrate metabolizing enzymes in mammary carcinoma rats51.
The mammary carcinoma-bearing mice showed decreased activity of mitochondrial TCA
cycle enzymes when compared with normal mice. Decreased activity of these enzymes might
be due to the alteration in the morphology and ultrastructure of cancer cells and the ability of
mitochondria to undergo metabolic changes when compared with normal cells, and also the
number of mitochondria was drastically reduced in tumor cells. The decrease in the
mitochondrial content might be due to the marked deficiency in one or electron transport
chain compounds59.We may speculate that tumor cells may be able to produce compounds
capable of being transported to normal host cells and act as uncoupling agents, thus lowering
ATP production in the normal tissues and contributing to tumor-induced cachexia60.
Enhanced mitochondrial lipid peroxidation has been reported to inactivate succinate oxidase,
succinate dehydrogenase and the components of the respiratory chain61.Further supporting
our observation, the decreased activity of succinate dehydrogenase and malate dehydrogenase
www.wjpps.com Vol 3, Issue 5, 2014.
1108
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
in kidney has been reported in gentamicin-induced nephrotoxicity62. Enhanced free radical
generation and the loss of mitochondrial respiration have been observed in Parkinson’s
disease, Alzheimer’s disease and cardiac ischemia/reperfusion injury51.
CONCLUSION
The results obtained in the present study indicate that deranged energy metabolism in N-
methyl-N-nitrosourea (MNU) induced mammary carcinoma in mice was rectified and
favorable restoration of glycolysis, HMP shunt enzyme and TCA cycle enzymes was
achieved by administration of Z.tetraspermum stem bark extract.
ACKNOWLEDGEMENT
The authors are thankful to Dr.R.Rajendran, Principal, P.S.G.College of Arts and Science,
Coimbatore-14, Dr.K.V.Surendran, Principal, Sree Narayana Guru College, Coimbatore,
Dr.V.P.Prabhakaran, Secretary, Sree Narayana Guru Educational Trust, Coimbatore for
giving permission to carry out this work.
REFERENCES
1. http://Imaginis.com/breasthealth/statistics.asp website. Breast Cancer: Statistics on
Incidence, Survival, and Screening. Imaginis: (2013).
2. Ali SM, Harvey HA, Lipton A. Metastatic breast cancer: overview of treatment. Clin
Orthop, 2003; 132-137.
3. Heimann R, Hellman S. Clinical progression of breast cancer malignant behavior: what to
expect and when to expect it. J Clin Oncol, 2000; 18: 591–599.
4. Lakhani SR.The transition from hyperplasia to invasive carcinoma of the breast. J. Pathol.,
1999; 187:272–278.
5. Subramaniam A, Pushpagadan P.Development of phytomedicines for liver diseases.
Ind.J.Pharmacol, 1999; Vol.3: 166-175.
6. Islam A, Sayeed A, Anwar-UI Islam M, Astaq Mohal Khan GRM, Biswas MHU, Shah
Alam Bhuiyan M. A flavonone from leaves of Zanthoxylum budrunga: Its In vitro
antimicrobial activity and cytotoxic
evaluation. J. Med. Sci., 2001; Vol.1: 209-213.
7. Ross SA, Sultana GN, Burandt CL, ElSohly MA, Marais JP, Ferreira D. Syncarpamide, a
new antiplasmodial (+)-norepinephrine derivative from Zanthoxylum syncarpum. J. Nat.
Prod., 2004; 67: 88-90.
www.wjpps.com Vol 3, Issue 5, 2014.
1109
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
8. Lima LM, Perazzo FF, Carvalho JCT, Bastos JK. Anti-inflammatory and analgesic
activities of the ethanolic extracts from Zanthoxylum riedelianum (Rutaceae) leave and
stem bark. J.Pharm. Pharmacol., 2007; 59: 1151-1158.
9. Chen JJ, Chen PH, Liao CH, Huang SY, Chen IS. New phenylpropenoids, bis (1-
phenylethyl) phenols, bisquinolinone alkaloid and anti-inflammatory constituents from
Zanthoxylum integrifoliolum.J.Nat.Prod, 2007; 70: 1444-1448.
10. Lee SJ, Lim KT.Glycoprotein of Zanthoxylum piperitum DC has a hepatoprotective effect
via anti-oxidative character In vivo and In vitro.Toxicol. In vitro, 2008; 22: 376-85.
11. Yang G, Chen D.Alkaloids from the roots of Zanthoxylum nitidum and their antiviral and
antifungal effects. Chem. Biodivers., 2008; 5(9): 1718-1722.
12. Peneluc T, Domingues LF, de Almeida GN, Ayres MC, Moreira EL, da Cruz AC, dos
Santos Calmon de Bittencourt TC, de Almeida MA, Batatinha MJ. Anthelmintic activity
of aqueous extract of Zanthoxylum rhoifolium Lam. leaves (Rutaceae). Rev. Bras.
Parasitol. Vet., 2009; 18: 43-48.
13. Song JH, Chae SW, Yoon KA, Park JS, Choi HJ.Antiviral Activity of Zanthoxylum
Species against Porcine Epidemic Diarrhea Virus. J. Cosmetics Pub. Health, 2010; 6: 42-
44.
14. Gansane A, Sanon S, Ouattara PL, Hutter S, Ollivier E, Azas N, Traore A, Traore AS,
Guissou IP, Nebie I, Sirima BS.Antiplasmodial activity and cytotoxicity of semi purified
fractions from Zanthoxylum
zanthoxyloides Lam. Bark of Trunk. Int. J. Pharmacol., 2010; 6: 921-925.
15. Guo T, Deng YX, Xie H, Yao CY, Cai CC, Pan SL, Wang YL.Antinociceptive and anti-
inflammatory activities of ethyl acetate fraction from Zanthoxylum armatum in mice.
Fitoterapia, 2011; 82: 347-351.
16. Chou ST, Chan HH, Peng HY, Liou MJ, Wu TS.Isolation of substances with
antiproliferative and apoptosis-inducing activities against leukemia cells from the leaves
of Zanthoxylum ailanthoides Sieb. Zucc. Phytomed, 2011; 18(5): 344-348.
17. Seal T.Determination of nutritive value, mineral contents and antioxidant activity of some
wild edible plants from Meghalaya State, India. Asian J. Appl. Sci., 2011; 4: 238-246.
18. Bishen Singh, Mahendrapal Singh, Nayar MP.Meaning of Indian flowering plant
names.1985; 367.
19.Ambasta SP.The wealth of India, Raw materials, CSIR, New Delhi.1998; Vol.9: X-Z: 17-
25.
www.wjpps.com Vol 3, Issue 5, 2014.
1110
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
20. Chandra YR.The useful plants of India, Publication and information Directorate, CSIR,
New Delhi. 1994; 697-699.
21. Hajra PK, Nair VJ, Daniel P. Flora of India, Botanical Survey of India, BSI, Calcutta,
1997; Vol.4: 389-390.
22. Kolayli S, Kucuk M, Yaylachi F, Dural N, Vsta M.Comparison of in vitro antioxidant
properties of trunk, bark of some tree species. Proceedings of ICNP, 2002; 133-139.
23. Perumal Samy R, Ignacimuthu S, Vincent TK.Chow. Evaluation of Antimicrobial Studies
of Traditional Medicine. Nature Proceedings, 2011; 6027 (1).
24. Nissanka APK, Karunaratne V, Ratnayake Bandara BM, Kumar V, Nakanishi T, Nishi M,
Inada A, Tillekeratne LMV, Wijesundara DSA, Gunatilaka AALO. Antimicrobial
alkaloids from Zanthoxylum tetraspermum and Zanthoxylum caudatum. Phytochemistry,
2001; 56 (8): 857-861.
25. Ravikumar VR, Gopal V, Sudha T. Analysis of Phytochemical constituents of stem bark
extracts of Zanthoxylum tetraspermum. Research J. Pharmace. Biolog. Chemic. Sciences,
2012; Vol.3 (4): 391-402.
26. Wan HC, Hu DY, Liu HC.Clinical observation of toothpaste containing Zanthoxylum
nitidum extract on dental plaque and gingivitis. Zhongguo Zhong Xi Yi Jie He Za Zhi,
2005; 25: 1024-1026.
27. Thouvenel C, Gantier JC, Duret P, Fourneau C, Hocquemiller R, Ferreira ME, de Arias
AR, Fournet A. Antifungal compounds from Zanthoxylum chiloperone var.
angustifolium. Phytother. Res., 2003; 17: 678-680.
28. Bafi-Yeboa NF, Arnason JT, Baker J, Smith ML.Antifungal constituents of Northern
prickly ash, Zanthoxylum americanum Mill. Phytomed., 2005; 12: 370-377.
29. Ross SA, Al-Azeib MA, Krishnaveni KS, Fronczek FR, Burandt CL. Alkamides from the
leaves of Zanthoxylum syncarpum. J.Nat. Prod., 2005; 68: 1297-1299.
30. Dieguez-Hurtado R, Garrido-Garrido G, Prieto-Gonzalez S, Iznaga Y, Gonzalez L,
Molina-Torres J, Curini M, Epifano F, Marcotullio MC.Antifungal activity of some
Cuban Zanthoxylum species. Fitoterapia, 2003;74: 384-386.
31. Islam A, Sayeed A, Bhuiyan MSA, Mosaddik MAG. In vitro Antimicrobial effect of three
Terpenes, Isolated from the Bark of Zanthoxylum budrunga. Pak. J. Biol. Sci., 2001; 4:
711-713.
32. Nissanka AP, Karunaratne V, Bandara BM, Kumar V, Nakanishi T, Nishi M, Inada A,
Tillekeratne LM, Wijesundara DS, Gunatilaka AA.Antimicrobial alkaloids from
Zanthoxylum tetraspermum and caudatum. Phytochemistry, 2001; 56: 857-861.
www.wjpps.com Vol 3, Issue 5, 2014.
1111
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
33. Da Silva SL, Figueiredo PM, Yano T. Cytotoxic evaluation of essential oil from
Zanthoxylum rhoifolium Lam. Leaves. Acta Amazonica, 2007; 37: 281-286.
34. Dongmo PMJ, Tchoumbougnang F, Tchinda SE, Manedong KS, Amvam ZPH, Menut C.
Antioxidant and anti-inflammatory potential of essential oils of some Zanthoxylum
(Rutaceae) of Cameroon. Int. J. Essent. Oil Therap., 2008; 2: 82-88.
35. Eigenbrodt E. Gerbracht, Mazurek S. Presek P. Friis R.Carbohydrate metabolism and
neoplasia: new perspective for diagnosis and therapy. In: Pretlow, T.G., Pretlow, T.P.
(Eds), Biochemical and molecular aspects of selected of CAN cerium, Academic Press,
Inc., 1994; Vol.(2): 311-385.
36. Sohal RS, Sohal BH.Hydrogen peroxide release by mitochondria increases during aging.
Mech. Ageing Dev. 1991; Vol.(57): 187-202.
37. Shoffner TM, Wallace DC.Oxidative phosphorylation disease and Mitochondrial DNA
mutations: diagnosis and treatment. Annu. Rev. Nutr., 1994; Vol.(14): 535-568.
38. Gamble JS.The flora of presidency of Madras, Botany-India, West Newman & Adlard
press, London: 1915; Vol.(1).
39. Branstrup N, Krik JE, Bruni C.The hexokinase and phosphoglucoisomerase activities of
aorta and pulmonary artery tissue in individuals of various ages. J. Gerontol. 1957;
Vol(12): 166-171.
40. King J.The phosphohydrolases acid and alkaline phosphatases. In: King, J. (ed.) Practical
and clinical enzymology, D.Van Nostrand Co.Ltd, London: 1965; 121-138.
41. Gracy RW, Tilley BE. Phosphoglucose isomerase of human erythrocytes and cardiac
tissue. Methods. Enzymol., 1975 ; Vol (41): 392- 400.
42. Ellls HA, Kirkman HM.A colorimetric method for assay of erythrocyte glucose-6-
phosphate dehydrogenase. Prac. Soc.Exp. Biol.Med., 1961; 106: 607-609.
43. Gancedo J M, Gancedo C.Fructose-1-6-bisphosphatase, phosphofructokinase and
glucose-6-phosphate dehydrogenase. Proc. Soc. Exp. Biol. Med. 1971; 106: 607-609.
44. Slater EC, Bonner WD.Effects of fluoride on succinate oxidase system. Biochem. J.,
1952; Vol(52): 185- 196.
45. Mehler A H, Kornberg A, Grisolia S, Ochoa S.The enzymatic mechanism of oxidation-
reductions between malate or isocitrate and pyruvate. J. Biol. Chem., 1948; 714: 961-977.
46. Taper SH., Roberfroid M.Influence of Insulin and oligo fructose on breast cancer and
tumor growth. J. Nutr., 1999; 129: 1488-1491.
47. Gerbracht U, Eigenbrodt E, Simile MM, Pascale RM, Gaspa L, Daino L, Seddaiu MA, De
Miglio MR, Nufris A, Feo F.Effect of S-adenosyl-L-methionine in the development of
www.wjpps.com Vol 3, Issue 5, 2014.
1112
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
preneoplastic foci and the activity of some carbohydrate metabolizing enzymes in the
liver, during experimental hepatocarcinogenesis. Anticancer Res., 1993; Vol(13): 1965-
1972.
48. Mathupale SP, Rempel A, Pedersen PL.Aberrant glycolytic metabolism of cancer cells: a
remarkable co-ordination of genetic, transcriptional, post translational and mutational
events that lead to a critical role for type II hexokinase. J. Bioenerg. Biomembr., 1997;
Vol(29): 339-343.
49. Golshani Hebroni SG, Bessman SP.Hexokinase binding to mitochondria, a basis for
proliferative energy metabolism. J. Bioenerg. Biomembr., 1997; Vol(29): 331-338.
50. Arora KK, Pederson PL.Functional; significance of mitochondrial bound hexokinase in
tumor cell metabolism. J. Biol. Chem., 1988; Vol(263): 1742-1748.
51. Arathi G, Sachdanandam P.Therapeutic effect of Semecarpus anacardium Linn. nut milk
extract on carbohydrate metabolizing and mitochondrial TCA cycle and respiratory chain
enzymes in mammary carcinoma rats. J. Pharmacy & Pharmaco., 2003; Vol(55): 1283 -
1290.
52. Mazurek S, Zwerschke W, Jansen-Duerr P, Eigenbrodt E.Effects of the human papilloma
virus Hpv-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase
type M2 and the glycolytic enzymes complex. Biochem. J., 2001;Vol(356): 247-256.
53. Campbell DK, King EJ.Serum phosphatases and glycolytic enzymes in cancer of the
breast.Biochemistry, 1962; Vol(82): 23-28.
54. Ebrahim AS, Babakrishnan K, Sakthisekaran D.Perchloroethylene-induced alterations in
glucose metabolism and their prevention by 2-deoxy-D-glucose and Vitamin-E in mice. J.
Appl. Toxicol., 1996; Vol(16): 339-348.
55. Racker E.From Pasteur to Mitchell: a hundred years of bioenergetics. Fed. Proc., 1980;
Vol(39): 210-215.
56. Sujatha V, Muthumanickam V, Rani G, Sachdanandam P.Effect of Semecarpus
anacardium Linn. nut extract on glucose metabolizing enzymes in experimentally
induced mammary carcinoma in rats. J. Pharm. Pharmacol., 1999; Vol(51): 241-244.
57. Suolinna M, Buchsbaum RN, Racker E.The effect of flavonoids and aerobic glycolysis
and growth of tumor cells. Cancer Res., 1975; Vol(35): 1865-1872.
58. Sujatha V, Sachdanandam P.Recuperative effect of Semecarpus anacardium Linn. nut
milk extract on the levels of few carbohydrate metabolizing enzymes in experimental
mammary carcinoma bearing rats. Phytother. Res., 2002; Vol(16): 514-518.
www.wjpps.com Vol 3, Issue 5, 2014.
1113
Narayanasamy et al. World Journal of Pharmacy and Pharmaceutical Sciences
59. Pederson PL.Tumor mitochondria and the bioenergetics of cancer cells. In: Progress in
experimental tumor research. Kargar, Basel, 1978; Vol(22): 190-274.
60. Argiles JM, Bieto JA.The metabolic environment of cancer. Mol. Cell. Biochem., 1988;
Vol(81): 3-17.
61. Tretter L, Szabaelos G, Ando A, Horvath T.Effect of succinate on mitochondrial lipid
peroxidation. The protective effect of succinate against functional and structural changes
induced by lipid peroxidation, J. Bioenerg. Biomembr., 1987; Vol(1): 31-44.
62. Sandhya P, Mohandass S, Varalakshmi P.Role of DL- A lipoic acid in gentamicin
induced nephrotoxicity. Mol. Cell. Biochem., 1995; Vol(145): 11-17.